Isoniazid-monoresistant tuberculosis in France: Risk factors, treatment outcomes and adverse events. (June 2021)

• Record Type: Journal Article
• Authors: Bachir, Marwa; Guglielmetti, Lorenzo; Tunesi, Simone; Billard-Pomares, Typhaine; Chiesi, Sheila; Jaffré, Jérémy; Langris, Hugo; Pourcher, Valérie; Schramm, Frédéric; Lemaître, Nadine; Robert, Jérôme; Bouchaud, O.; Billard-Pomares, T.; Carbonnelle, E.; Mechaï, F.; Nunes, H.; Pellan, M.; Morin, A.-S.; Dumesnil, C.; Dumoulin, J.; Roux, A.-L.; Jachym, M.; le Du, D.; Marigot-Outtandy, D.; Abgrall, S.; Chambrin, V.; Guillet, C.; Fantin, B.; Galy, A.; Decousser, J.-W.; Lelièvre, J.D.; Gallien, S.; Nebbad-Lechani, B.; Deconinck, L.; Bulifon, S.; Fortineau, N.; Wyplosz, B.; Cohen, F.; Lemaitre, N.; Crestani, B.; Grall, N.; Pierre-Audigier, C.; Rioux, C.; Yazdanpanah, Y.; Le Jeunne, C.; Morand, P.; Roche, N.; Pavie, J.; Loulergue, P.; Delcey, V.; Lecorché, E.; Munier, A.-L.; Mougari, F.; Sellier, P.; Bille, E.; Ferroni, A.; Guéry, R.; Hummel, A.; Lourenco, J.; Aubry, A.; Bonnet, I.; Caumes, E.; Londner, C.; Morel, F.; Lacombe, K.; Lalande, V.; Meynard, J.-L.; Veziris, N.; De Castro, N.; Denis, B.; Lafaurie, M.; Molina, J.-M.; Canestri, A.; Lassel, L.; Pialoux, G.; Verdet, C.; Nardi, A.-L.; Gominet, M.; Catherinot, E.;
• Is Part Of: International journal of infectious diseases. Volume 107(2021)
• Page Start: 86
• Page End: 91
• Publication Date: 2021-06
• Subjects: Tuberculosis -- Isoniazid -- Drug resistance -- Risk factors -- Epidemiology; Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; Electronic journals; 616.9
• DOI: 10.1016/j.ijid.2021.03.093
• Languages: English
• ISSNs: 1201-9712

Abstract

Highlights: No specific risk factors for isoniazid-monoresistant tuberculosis (HR-TB) identified. Routine implementation of line probe assays on clinical samples is warranted. In France HR-TB treatment outcomes are comparable to those for drug-susceptible TB. Abstract: Objectives: Isoniazid-monoresistant tuberculosis (HR-TB) is the most prevalent form of drug-resistant TB worldwide and in France and is associated with poorer treatment outcomes compared with drug-susceptible TB (DS-TB). The objective of this study was to determine the characteristics of HR-TB patients in France and to compare outcomes and safety of treatment for HR-TB and DS-TB. Methods: We performed a case-control multicenter study to identify risk factors associated with HR-TB and compare treatment outcomes and safety between HR-TB patients and DS-TB patients. Results: Characteristics of 99 HR-TB patients diagnosed and treated in the university hospitals of Paris, Lille, Caen and Strasbourg were compared with 99 DS-TB patients. Female sex (OR = 2.2; 1.0–4.7), birth in the West-Pacific World Health Organization region (OR = 4.6; 1.1–18.7) and resistance to streptomycin (OR = 77.5; 10.1–594.4) were found to be independently associated with HR-TB. Rates of treatment success did not differ significantly between HR-TB and DS-TB. Conclusions: Factors associated with HR-TB are not significant enough to efficiently screen TB patients at risk of HR-TB. The systematic implementation of rapid molecular testing on clinical samples remains the only effective way to make the early diagnosis of HR-TB and adapt treatment.